Market Cap $3,786,063,229,829
24h Volume $99,081,709,333
BTC Market Cap $1,928,707,215,521
BTC Dominance 50.9%

HEX Live Price Update & Market Capitalization

HEX HEX Rank #541

$0.003086 2.83%

Market Overview

HEX current market price is $0.003086 with a 24 hour trading volume of $40,065. The total available supply of HEX is 0 HEX. It has secured Rank 541 in the cryptocurrency market with a marketcap of $0. The HEX price is 2.83% down in the last 24 hours.

The volume-weighted average price of the HEX is $0.002937 in the last 24 hours. Live prices from all markets and coin market Capitalization. Stay up to date with the latest price movements. Check our coin stats data and see when there is an opportunity to buy or sell at best price in the market.

Buy HEX (HEX)

Sell HEX (HEX)

HEX Rank

541

HEX Price

$0.003086

VWAP (24h)

$0.002937

Price Change (24h)

2.83%

Market Cap

Trading Volume (24H)

$40,065

Circulating Supply

0 HEX

Max Supply

(Not Available)

Cryptocurrency HEX Calculator

Want to convert more cryptocurrencies?

Use Crypto Calculator

HEX Historical Data Price Chart

HEX Markets Exchange Data

Compare live prices of HEX on top exchanges.

#	Exchange	Pair	Price	Volume (24h)	Volume (%)
	Bilaxy	HEX/ETH	$0.003087	$40,075	100%

Cryptocurrency Latest News & Updates

ETH/BTC pair hits YTD low as Bitcoin dominance surges

ETH/BTC hits its lowest level this year as Bitcoin soars to a new all-time high, fueling market dominance debates....

Crypto murder: Two more arrested in Montreal crypto influencer case

Two additional arrests have been made in the case of Kevin Mirshahi, a cryptocurrency influencer whose body was discovered in a Montreal park last month. Quebec provincial police announced that Darius Perry, 27, and Nackael Hickey, 25, face charges of…...

Nasdaq-listed antibiotics developer Acurx to put $1m in Bitcoin on balance sheet

Public biopharmaceutical company Acurx Pharmaceuticals said it plans to buy up to $1 million worth of Bitcoin to hold as a “treasury reserve asset.” Acurx Pharmaceuticals, a biopharmaceutical company developer new antibiotics for hard-to-treat bacterial infections, is set to purchase…...